Sicagen India (533014)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at 58% of book value (P/B 0.58 vs book value ₹109.92), providing a large stated margin of safety.
• P/E of 11.73 and PEG of 0.19 suggest cheap valuation if recent growth can persist.
• Sales growth of 25.89% and profit growth of 100.39% show strong recent momentum.
• Piotroski F-score of 7/9 indicates improving fundamentals and financial health.
• Dividend yield of 1.90% rewards shareholders while awaiting value realisation.

Concerns

• Low ROE of 3.06% and ROCE of 5.57% reflect poor capital productivity and likely sub-cost-of-capital returns.
• Trading/distribution business inherently has weak pricing power and little durable competitive advantage.
• Reported profit growth of 100.39% is flattered by a low base; latest quarter net margin is only ~1.9%.
• Debt/Equity and promoter holding are not disclosed, so balance-sheet risk cannot be fully assessed.

AI Analysis

Let me start with the Graham way: at ₹63.49, against book value of ₹109.92, I am buying a rupee of assets for 58 paise. That discount is the most attractive thing on this page. But a low P/B is not enough if the business cannot earn a respectable return on those assets. ROE is just 3.06% and ROCE is 5.57%. For a trading and distribution company, margins are thin and moats are almost non-existent; the latest quarter illustrates this: sales of ₹264 Cr yielded only ₹5 Cr of net profit, a margin of about 1.9%. There is real growth -- sales rose 25.89% and profit rose 100.39% -- but those numbers come from a low base and the PEG of 0.19 assumes that this profit growth can be extrapolated. I would be cautious. The Piotroski F-score of 7 out of 9 does give me some comfort: the financial health is improving. The dividend yield of 1.90% offers a small return while I wait. Still, I cannot call this a great business; it is a mediocre business at a cheap price. If book value is genuine and management uses the discounted stock price wisely, patient investors may get a decent return. I would need to see ROE trend closer to 10% or better, consistent cash flow, and no hidden debt trouble. Until then, this is an asset play, not a compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer